ReviewMalaria journal2025
Natural products as transmission-blocking agents against malaria: a comprehensive review of bioactive compounds and their therapeutic potential.
Review in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In- vitro assessment of the anti- malarial potential of Alpha Onocerin; cytotoxicity and hemolytic effect, multi-stage activity and molecular docking.BMC pharmacology & toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria eradication is hindered by the persistence of transmission stages of Plasmodium falciparum that enable parasite transfer from humans to mosquitoes. Current therapeutic strategies, such as artemisinin-based combination therapy (ACT) combined with primaquine, are insufficient due to limited efficacy on mature gametocytes and safety concerns in populations with glucose-6-phosphate dehydrogenase deficiency. This highlights the critical need for innovative, safe, and effective transmission-blocking interventions. This review explores the potential of natural sources, including medicinal plants, marine organisms, and microorganisms-as reservoirs of novel bioactive compounds with anti-malarial properties. A comprehensive literature search identified promising natural products with gametocytocidal and sporontocidal activity, validated through advanced bioassays. The review also evaluates various methodologies, such as colorimetric, microscopy, and flow cytometry assays, for assessing transmission-blocking efficacy. The findings emphasize the potent gametocytocidal effects of certain plant extracts, such as Azadirachta indica and Vernonia amygdalina, and microbial products, including ionophores and proteasome inhibitors. Despite promising in vitro and in vivo data, the transition of these compounds to clinical applications remains limited. Challenges include standardizing assays, addressing resistance to current therapies, and ensuring drug safety for endemic populations. The current review underscores the untapped potential of natural products as transmission-blocking agents and proposes a systematic, stage-specific screening cascade to identify and optimize these compounds. Addressing these gaps could significantly advance global malaria eradication efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.